HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer

Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Koreckij, Theodore D, Trauger, Richard J, Montgomery, Robert Bruce, Pitts, Tiffany EM, Coleman, Ilsa, Nguyen, Holly, Reading, Chris L, Nelson, Peter S, Vessella, Robert L, Corey, Eva
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Neoplasia Press Inc. 2009
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2767223/
https://ncbi.nlm.nih.gov/pubmed/19881957
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak